The earnings call highlighted significant strategic progress with Medicaid pilot programs and leadership appointments, but financial metrics such as revenue decline and increased operating expenses present ongoing challenges.
Company Guidance
During the Sera Prognostics conference call to review third-quarter fiscal year 2025 results, the company highlighted several key metrics and strategic initiatives. Net revenue for the quarter was reported at $16,000, a decrease from $29,000 in the same period last year, attributed to the transition towards the commercialization of the PreTRM Test. The company recorded total operating expenses of $9.0 million, with research and development expenses decreasing to $3.3 million and selling, general, and administrative expenses rising to $5.7 million. Sera Prognostics emphasized progress in its Medicaid pilot programs, particularly in Nevada, and is engaging with 10 payers across 13 states, covering approximately 33% of U.S. births and 35% of Medicaid births annually. The company also reported cash and cash equivalents of $102.4 million as of September 30, 2025, and highlighted its strategic focus on achieving payer coverage and physician adoption. Looking ahead, Sera Prognostics remains on track to publish the full results of its PRIME study by the end of the year and is preparing for broader commercialization efforts, including expanding its sales force in target states.
Geographically Focused Commercial Strategy
The company is advancing its geographically focused strategy to achieve payer coverage and physician education, with significant progress in Medicaid plan pilot programs in Nevada and discussions in 13 states.
Leadership Appointments
High-impact leadership appointments include Dr. Tiffany Inglis as Chief Medical Officer and Marisol Urbano as Head of Commercial Operations, enhancing the company's strategic direction and commercial operations.
First Medicaid Pilot Launch
The inaugural Medicaid pilot in Nevada is actively enrolling patients, marking a significant step in the company's commercialization strategy.
Sera Prognostics (SERA) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SERA Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 13, 2025
$2.95
$2.96
+0.34%
Aug 06, 2025
$2.75
$2.60
-5.45%
May 07, 2025
$2.40
$2.12
-11.67%
Mar 19, 2025
$4.14
$3.93
-5.07%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Sera Prognostics, Inc. (SERA) report earnings?
Sera Prognostics, Inc. (SERA) is schdueled to report earning on Mar 25, 2026, After Close (Confirmed).
What is Sera Prognostics, Inc. (SERA) earnings time?
Sera Prognostics, Inc. (SERA) earnings time is at Mar 25, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.